TY  - JOUR

T1  - Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden

JO  - Cardiology and Therapy

UR  - http://eprints.whiterose.ac.uk/115425/

PY  - 2015/12/01

AU  - Begum N

AU  - Stephens S

AU  - Schoeman O

AU  - Fraschke A

AU  - Kirsch B

AU  - Briere J-B

AU  - Verheugt FWA

AU  - van Hout BA

ED  - 

DO  - DOI: 10.1007/s40119-015-0041-3

VL  - 4

IS  - 2

SP  - 131

EP  - 153

Y2  - 2024/12/22

ER  -